Abond CRO Announces That Mr. Zoran Antonijevic Is Their New Vice President, Statistical Consulting

ALLENDALE, Mich.--(BUSINESS WIRE)--Feb 23, 2021--

Dr. Phil Doren, Chief Executive Officer and Vice President, is pleased to announce today that Zoran Antonijevic is the Vice President, Statistical Consulting at Abond CRO Inc. “With this single appointment, we have greatly strengthened our capability to address customers’ needs in statistical consulting for drug development,” Doren said.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005655/en/

(Photo: Business Wire)

Mr. Antonijevic is an industry thought leader with cutting edge knowledge of innovative methods and strategies including adaptive design, platform trials, and program/portfolio optimization. He has extensive experience with drug development, department development and decision making. He is the long-time Chair and leader of the DIA Adaptive Design Scientific Working Group. His background covers numerous therapeutic areas and his professional strengths include development strategy, thought leadership and vision, consulting, program and portfolio level optimization, master protocols, decision science, analytics, due diligence, regulatory, department vision, processes and metrics and talent identification.

Prior to coming to Abond CRO, Mr. Antonijevic’s CRO experience included leading Biometrics, where he managed all biostatistics, programming, data management and medical writing activities, and previously he was Senior Director of Strategy, and the Senior Director/Director, Center for Statistics in Drug Development Innovation.

His experience at major pharmaceutical companies includes Innovative & Adaptive Design Executive Director and Head of Development Design Center, and, very early in his career, was a Principal Statistician.

Mr. Antonijevic formed his own consulting company and while doing that work, served as Chief Scientific Officer for a global health firm specializing in highly-efficient clinical study designs and biostatistical methods. He began his career at the Harvard School of Public Health, AIDS Clinical Trials Group (ACTG).

“Abond CRO is excited to have Zoran join our company. His leadership, experience and amazing technical expertise greatly enhances our foundational and long-standing tradition of excellent direction and support in statistical consulting for our customers,” Doren added.

About Abond CRO Inc. ( www.abondcro.com )

Abond is a full-service clinical research organization dedicated to providing specialized clinical research support for the pharmaceutical and medical device industries since its founding in 1974 (incorporation in 1985). They deliver everything you’d expect from a full-service CRO — consulting, clinical operations, data management, statistical analysis — and a few things that set them apart: honesty, focus, and responsibility. Abond works with small startup organizations to established pharmaceutical and medical device leaders around the world.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210223005655/en/


Charley Bratton





SOURCE: Abond CRO Inc.

Copyright Business Wire 2021.

PUB: 02/23/2021 04:45 PM/DISC: 02/23/2021 04:45 PM


Copyright Business Wire 2021.

Recommended for you

(0) comments

Welcome to the discussion.

Real Names required. No pseudonyms or partial names allowed. Stand behind what you post.
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.

Thank you for reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.